Acute myeloid leukemia

Results from the phase II study of WT1 first-in-class immunotherapeutic anti-cancer treatment in multiple myeloma patients following autologous stem cell...


The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy designation to PKC412 ( Midostaurin ). Midostaurin is...


Positive results from the global phase III RATIFY ( CALGB 10603 ) clinical trial were announced. In the study, adult...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated...


Treatment outcomes for older patients with acute myeloid leukemia ( AML ) have remained dismal. A randomized, phase 2 trial...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Lynparza ( Olaparib ), a new drug...


Early results of a randomized phase III GITMO/FIL study comparing CHOP-R vs. R-HDS + ASCT as primary treatment in 134...


Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review...


Many mutations that contribute to the pathogenesis of acute myeloid leukemia ( AML ) are undefined. The relationships between patterns...


T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation ( HSCT ) is a suitable option for patients in need of an...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed...


Researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of...


The results from AZA-001 are published in The Lancet Oncology. The data indicate that Vidaza ( Azacitidine ) demonstrated a...


A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed...


A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with...


MD Anderson researchers show Sorafenib targets AML driven by mutant FLT3 gene HOUSTON - A drug used to treat kidney...


A 5-year follow-up of patients with chronic myeloid leukemia ( CML ) who began continuous treatment with Imatinib ( Glivec...